- STAT+: No Surprises Act arbitration rule could worsen flood of provider disputesThe arbitration process has protected patients but generated financial windfalls for some clinicians.STAT · 1mo ago↗ source
- STAT+: A standing ovation for RevMed, and caution for AkesoASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.STAT · 1mo ago↗ source
- Ultra-low doses could bring costly cancer treatments to more patients in poorer countriesLow-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.STAT · 1mo ago↗ source